EFFICACY AND SAFETY OF TELITACICEPT, A NOVEL BLYS/APRIL DUAL INHIBITOR, IN PATIENTS WITH PRIMARY SJOGREN'S SYNDROME: A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED 24-WEEK STUDY

被引：1
|
作者：
Xu, D. [1 ]
Zhang, S. [1 ]
Huang, C. [2 ,3 ]
Huang, C. [2 ,3 ]
Qin, L. [4 ]
Li, X. [5 ]
Chen, M. [6 ]
Liu, X. [7 ]
Liu, Y. [8 ]
Li, Z. [9 ]
Hu, J. [10 ]
Bao, C. [11 ]
Wei, W. [12 ]
Tian, J. [13 ]
Duan, X. [14 ]
Van Vollenhoven, R. [15 ]
Fang, J. [16 ,17 ]
Zeng, X. [1 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Rheumatol, Beijing, Peoples R China
[2] Beijing Hosp, Rheumatol, Beijing, Peoples R China
[3] Guangzhou Med Univ, Affiliated Hosp 2, Rheumatol, Guangzhou, Peoples R China
[4] Huzhou Third Municipal Hosp, Rheumatol, Huzhou, Peoples R China
[5] Anhui Prov Hosp, Rheumatol, Hefei, Anhui, Peoples R China
[6] Xiamen Univ, Affiliated Hosp 1, Rheumatol, Xiamen, Peoples R China
[7] Shanxi Med Univ, Hosp 1, Rheumatol, Taiyuan, Shanxi, Peoples R China
[8] Sichuan Univ, West China Hosp, Rheumatol, Chengdu, Sichuan, Peoples R China
[9] Bengbu Med Coll, Affiliated Hosp 1, Rheumatol, Bengbu, Peoples R China
[10] Jiangxi Pingxiang Peoples Hosp, Rheumatol, Jianxi, Peoples R China
[11] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Rheumatol, Shanghai, Peoples R China
[12] Tianjin Med Univ, Gen Hosp, Rheumatol, Tianjin, Peoples R China
[13] Cent South Univ, Xiangya Hosp 2, Rheumatol, Xiangya, Peoples R China
[14] Nanchang Univ, Affiliated Hosp 2, Rheumatol, Nanchang, Jiangxi, Peoples R China
[15] Univ Amsterdam, Rheumatol, Med Ctr, Amsterdam, Netherlands
[16] Shanghai Tongi Univ, Rheumatol, Shanghai, Peoples R China
[17] RemeGen Co Ltd, Rheumatol, Yantai, Peoples R China
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
Clinical Trials; Randomized control trial; Sjogren syndrome;
D O I：
10.1136/annrheumdis-2023-eular.1728
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP0142
引用
收藏
页码：94 / 95
页数：2
相关论文
共 50 条
  • [41] Efficacy and Safety of Mirtazapine in Fibromyalgia Syndrome Patients: A Randomized Placebo-Controlled Pilot Study
    Yeephu, Suwimon
    Suthisisang, Chuthamanee
    Suttiruksa, Saithip
    Prateepavanich, Pradit
    Limampai, Patchara
    Russell, Irwin Jon
    ANNALS OF PHARMACOTHERAPY, 2013, 47 (7-8) : 921 - 932
  • [42] A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease - Pilot Study
    Prasher, VP
    Huxley, A
    Haque, MS
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2002, 17 (03) : 270 - 278
  • [43] Ianalumab (VAY736) Safety and Efficacy in Patients with Sjogren's Syndrome: 52 Week Results from a Randomized, Placebo-controlled, Phase 2b Dose-ranging Trial
    Doerner, Thomas
    Bowman, Simon J.
    Fox, Robert
    Mariette, Xavier
    Papas, Athena
    Grader-Beck, Thomas
    Fisher, Ben A.
    Barcelos, Filipe
    De Vita, Salvatore
    Schulze-Koops, Hendrik
    Moots, Robert
    Junge, Guido
    Woznicki, Janice
    Sopala, Monika
    Luo, Wen-Lin
    Hueber, Wolfgang
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 2063 - 2065
  • [44] IANALUMAB (VAY736) SAFETY AND EFFICACY IN PATIENTS WITH SJOGREN'S SYNDROME: 52 WEEK RESULTS FROM A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2B DOSE-RANGING TRIAL
    Doerner, T.
    Bowman, S. J.
    Fox, R.
    Mariette, X.
    Papas, A.
    Grader-Beck, T.
    Fisher, B. A.
    Barcelos, F.
    De Vita, S.
    Schulze-Koops, H.
    Moots, R. J.
    Junge, G.
    Woznicki, J.
    Sopala, M.
    Luo, W.
    Hueber, W.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2022, 40 (12) : 87 - 88
  • [45] Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease - A 24-week, multicenter, double-blind, placebo-controlled study in Japan
    Homma, A
    Takeda, M
    Imai, Y
    Udaka, F
    Hasegawa, K
    Kameyama, M
    Nishimura, T
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2000, 11 (06) : 299 - 313
  • [46] A 24-Week Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of Once-Daily Umeclidinium/vilanterol 125/25 Mcg In COPD
    Celli, B. R.
    Crater, G.
    Kilbride, S.
    Mehta, R.
    Tabberer, M.
    Kalberg, C. J.
    Church, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [47] Muraglitazar, a dual (α/γ) PPAR activator:: A randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes
    Buse, JB
    Rubin, CJ
    Frederich, R
    Viraswami-Appanna, K
    Lin, KC
    Montoro, R
    Shockey, G
    Davidson, JA
    CLINICAL THERAPEUTICS, 2005, 27 (08) : 1181 - 1195
  • [48] EFFECT OF IBERDOMIDE ON CUTANEOUS MANIFESTATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF A 24-WEEK, PLACEBO-CONTROLLED, PHASE 2 STUDY
    Werth, V.
    Merrill, J.
    Furie, R.
    Doerner, T.
    Van Vollenhoven, R.
    Lipsky, P.
    Weiswasser, M.
    Korish, S.
    Schafer, P.
    Stern, M.
    Liu, Z.
    Tang, S.
    Delev, N.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 76 - 77
  • [49] APRIL and BAFF Levels After Rituximab Treatment in Patients with Primary Sjogren's Syndrome: A Placebo-Controlled Clinical Trial
    Pollard, Rodney
    Abdulahad, Wayel H.
    Huitema, Minke G.
    Visser, Annie
    Meijer, Jiska
    Burgerhof, Hans
    Spijkervet, Fred
    Kallenberg, Cees G. M.
    Vissink, Arjan
    Kroese, Frans
    Bootsma, Hendrika
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S687 - S687
  • [50] A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjogren's syndrome
    Juarez, Maria
    Diaz, Nieves
    Johnston, Geoffrey, I
    Nayar, Saba
    Payne, Andrew
    Helmer, Eric
    Cain, Dionne
    Williams, Paulette
    Devauchelle-Pensec, Valerie
    Fisher, Benjamin A.
    Giacomelli, Roberto
    Gottenberg, Jacques-Eric
    Guggino, Giuliana
    Kvarnstrom, Marika
    Mariette, Xavier
    Ng, Wan Fai
    Rosas, Jose
    Burson, Juan Sanchez
    Triolo, Giovanni
    Barone, Francesca
    Bowman, Simon J.
    RHEUMATOLOGY, 2021, 60 (03) : 1364 - 1375
12345